Precision BioSciences, Inc. (NASDAQ:DTIL) Given Average Rating of “Moderate Buy” by Analysts

Precision BioSciences, Inc. (NASDAQ:DTIL) has earned a consensus recommendation of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $32.25.

A number of research analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. Oppenheimer started coverage on Precision BioSciences in a report on Tuesday. They issued an “outperform” rating and a $20.00 price objective for the company. Wall Street Zen raised Precision BioSciences from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. JonesTrading restated a “buy” rating and set a $30.00 price target on shares of Precision BioSciences in a research note on Friday, April 17th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $19.00 price target on shares of Precision BioSciences in a research report on Friday, March 13th.

Precision BioSciences Trading Up 4.2%

Precision BioSciences stock opened at $6.77 on Tuesday. Precision BioSciences has a one year low of $3.53 and a one year high of $8.82. The business’s fifty day moving average is $6.99 and its 200 day moving average is $5.45. The stock has a market capitalization of $174.67 million, a PE ratio of -1.84 and a beta of 1.30. The company has a debt-to-equity ratio of 0.29, a current ratio of 14.02 and a quick ratio of 14.02.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Tuesday, May 5th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). The business had revenue of $10.84 million during the quarter, compared to analysts’ expectations of $4.05 million. Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%. On average, sell-side analysts predict that Precision BioSciences will post -1.29 EPS for the current year.

Institutional Trading of Precision BioSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its stake in shares of Precision BioSciences by 167.6% during the 1st quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock worth $151,000 after acquiring an additional 17,172 shares during the last quarter. Quantinno Capital Management LP purchased a new stake in shares of Precision BioSciences in the 1st quarter worth $104,000. Octagon Capital Advisors LP raised its holdings in Precision BioSciences by 16.6% in the 1st quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock worth $12,302,000 after purchasing an additional 318,737 shares during the period. Affinity Asset Advisors LLC purchased a new position in Precision BioSciences during the first quarter valued at $3,289,000. Finally, XTX Topco Ltd bought a new stake in Precision BioSciences during the fourth quarter valued at about $149,000. 37.99% of the stock is owned by hedge funds and other institutional investors.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.